Clinical Trial

A Study of SGB-3383 in Healthy Subjects

Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) effects of SGB-3383 in healthy subjects. The study will be designed as a single ascending dose (SAD) phase, utilizing a double-blind, placebo-controlled approach.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-05-20.
Trial Details
NCT Number NCT06995326
Lead Sponsor Suzhou Sanegene Bio Inc.
Conditions Healthy Volunteers
Enrollment 37 participants
Start Date 2025-06
Primary Completion 2026-08 (estimated)
Study Completion 2027-01 (estimated)
Updated on ClinicalTrials.gov 2025-06-03